Mito-Tempol and Dexrazoxane Exhibit Cardioprotective and Chemotherapeutic Effects through Specific Protein Oxidation and Autophagy in a Syngeneic Breast Tumor Preclinical Model

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Dickey, Jennifer S ^a,e   Gonzalez, Yanira ^a   Aryal, Baikuntha ^a   Mog, Steven ^a   Nakamura, Asako J ^b,f   Redon, Christophe E ^b   Baxa, Ulrich ^c   Rosen, Elliot ^a   Cheng, Gang ^d   Zielonka, Jacek ^d   Parekh, Palak ^b   Mason, Karen P ^a   Joseph, Joy ^d   Kalyanaraman, Balaraman ^d   Bonner, William ^b   Herman, Eugene ^a   Shacter, Emily ^a   Rao, V Ashutosh ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d FREE RADICAL RESEARCH CENTER   (United States)

^e CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^f IBARAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; CASPASE 3; CELL PROTEIN; DOXORUBICIN; INTERLEUKIN 1ALPHA; MITOCHONDRIALY TARGETED TEMPOL 4; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN LC3 II; RAZOXANE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BIOACCUMULATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART PROTECTION; HEART WEIGHT; HISTOPATHOLOGY; MASS SPECTROMETRY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROTEIN CARBONYLATION; PROTEIN METABOLISM; RAT; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; TUMOR VOLUME; TWO DIMENSIONAL ELECTROPHORESIS; WEIGHT REDUCTION;

ANIMALS; ANTIOXIDANTS; AUTOPHAGY; BREAST NEOPLASMS; CELL LINE, TUMOR; DEXRAZOXANE; DISEASE MODELS, ANIMAL; FEMALE; MICROTUBULE-ASSOCIATED PROTEINS; MITOCHONDRIA, HEART; ORGANOPHOSPHORUS COMPOUNDS; OXIDATION-REDUCTION; PIPERIDINES; PROTEIN CARBONYLATION; RATS; RATS, INBRED SHR;

EID: 84881115392     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070575     Document Type: Article

References (57)

1. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, et al. (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102: 14-25.
2. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, et al. (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28: 3910-3916.
3. Mellor HR, Bell AR, Valentin JP, Roberts RR (2011) Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci: 14-32.
4. Ferrans VJ, Clark JR, Zhang J, Yu ZX, Herman EH, (1997) Pathogenesis and prevention of doxorubicin cardiomyopathy. Tsitologiia 39: 928-937.
5. Levine RL, Stadtman ER, (2001) Oxidative modification of proteins during aging. Exp Gerontol 36: 1495-1502.
6. Shacter E, Williams JA, Lim M, Levine RL, (1994) Differential susceptibility of plasma proteins to oxidative modification: examination by western blot immunoassay. Free Radic Biol Med 17: 429-437.
7. Olson RD, Boerth RC, Gerber JG, Nies AS, (1981) Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci 29: 1393-1401.
8. Herman EH, Zhang J, Chadwick DP, Ferrans VJ, (2000) Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol 45: 329-334.
9. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, et al. (2007) Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109: 896-904.
10. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
11. Doggrell SA, Brown L, (1998) Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 39: 89-105.
12. Rao VA, Zhang J, Klein SR, Espandiari P, Knapton A, et al. (2011) The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol 68: 1125-1134.
13. Lindpaintner K, Kreutz R, Ganten D, (1992) Genetic variation in hypertensive and 'control' strains. What are we controlling for anyway? Hypertension 19: 428-430.
14. Folkow B, (1993) Early structural changes in hypertension: pathophysiology and clinical consequences. J Cardiovasc Pharmacol 22Suppl 1: S1-6.
15. Herman EH, Ferrans VJ, (1998) Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol 25: 15-21.
16. Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, et al. (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17: 2237-2243.
17. Herman EH, el-Hage A, Ferrans VJ, (1988) Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol 92: 42-53.
18. McDonnell AM, Nowak AK, Lake RA, (2011) Contribution of the immune system to the chemotherapeutic response. Semin Immunopathol 33: 353-367.
19. Nagayasu H, Hamada J, Kawano T, Konaka S, Nakata D, et al. (1998) Inhibitory effects of malotilate on invasion and metastasis of rat mammary carcinoma cells by modifying the functions of vascular endothelial cells. Br J Cancer 77: 1371-1377.
20. Hamada J, Nagayasu H, Takayama M, Kawano T, Hosokawa M, et al. (1995) Enhanced effect of epidermal growth factor on pulmonary metastasis and in vitro invasion of rat mammary carcinoma cells. Cancer Lett 89: 161-167.
21. Hamada J, Takeichi N, Kobayashi H, (1987) Inverse correlation between the metastatic capacity of cell clones derived from a rat mammary carcinoma and their intercellular communication with normal fibroblasts. Jpn J Cancer Res 78: 1175-1178.
22. Yuhki N, Hamada J, Kuzumaki N, Takeichi N, Kobayashi H, (1986) Metastatic ability and expression of c-fos oncogene in cell clones of a spontaneous rat mammary tumor. Jpn J Cancer Res 77: 9-12.
23. Kimmelman AC, (2011) The dynamic nature of autophagy in cancer. Genes Dev 25: 1999-2010.
24. Rao VA, Klein SR, Bonar SJ, Zielonka J, Mizuno N, et al. (2010) The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitoquinone. J Biol Chem 285: 34447-34459.
25. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, et al. (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11: 950-961.
26. Kruit WH, Punt KJ, Goey SH, de Mulder PH, van Hoogenhuyze DC, et al. (1994) Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication. Cancer 74: 2850-2856.
27. Hasinoff BB, Chee GL, Thampatty P, Allan WP, Yalowich JC, (1999) The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis. Anticancer Drugs 10: 47-54.
28. Ferte C, Massard C, Cohen A, Soria JC, Ederhy S, (2010) Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients? Am J Clin Oncol 35: 183-184.
29. Hahn SM, Krishna CM, Samuni A, DeGraff W, Cuscela DO, et al. (1994) Potential use of nitroxides in radiation oncology. Cancer Res 54: 2006s-2010s.
30. Monti E, Cova D, Guido E, Morelli R, Oliva C, (1996) Protective effect of the nitroxide tempol against the cardiotoxicity of adriamycin. Free Radic Biol Med 21: 463-470.
31. Trnka J, Blaikie FH, Logan A, Smith RA, Murphy MP, (2009) Antioxidant properties of MitoTEMPOL and its hydroxylamine. Free Radic Res 43: 4-12.
32. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, et al. (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61: 154-171.
33. Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, et al. (1994) In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 54: 1702-1706.
34. Hamada J, Takeichi N, Kobayashi H, (1988) Metastatic capacity and intercellular communication between normal cells and metastatic cell clones derived from a rat mammary carcinoma. Cancer Res 48: 5129-5132.
35. Billingham ME, Mason JW, Bristow MR, Daniels JR, (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 62: 865-872.
36. Redon CE, Nakamura AJ, Sordet O, Dickey JS, Gouliaeva K, et al. (2011) gamma-H2AX detection in peripheral blood lymphocytes, splenocytes, bone marrow, xenografts, and skin. Methods Mol Biol 682: 249-270.
37. Levine RL, Wehr N, Williams JA, Stadtman ER, Shacter E, (2000) Determination of carbonyl groups in oxidized proteins. Methods Mol Biol 99: 15-24.
38. Aluise CD, Miriyala S, Noel T, Sultana R, Jungsuwadee P, et al. (2011) 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-alpha release: implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic Biol Med 50: 1630-1638.
39. Shacter E, Weitzman SA (2002) Chronic inflammation and cancer. Oncology (Williston Park) 16: 217-226, 229; discussion 230-212.
40. Redon CE, Dickey JS, Nakamura AJ, Kareva IG, Naf D, et al. (2010) Tumors induce complex DNA damage in distant proliferative tissues in vivo. Proc Natl Acad Sci U S A 107: 17992-17997.
41. Doroshow JH, Synold TW, Somlo G, Akman SA, Gajewski E, (2001) Oxidative DNA base modifications in peripheral blood mononuclear cells of patients treated with high-dose infusional doxorubicin. Blood 97: 2839-2845.
42. Samuni Y, Cook JA, Choudhuri R, Degraff W, Sowers AL, et al. (2010) Inhibition of adipogenesis by Tempol in 3T3-L1 cells. Free Radic Biol Med 49: 667-673.
43. Herman EH, Zhang J, Rifai N, Lipshultz SE, Hasinoff BB, et al. (2001) The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 48: 297-304.
44. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, et al. (2008) gammaH2AX and cancer. Nat Rev Cancer 8: 957-967.
45. Tanaka T, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z, (2006) Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants. Cell Cycle 5: 1940-1945.
46. Nishio N, Oishi K, Machida K, (2003) SST-2 tumor inoculation is a useful model for studying the anti-tumor immune response in SHR rats. Environ Health Prev Med 8: 1-5.
47. Lu L, Wu W, Yan J, Li X, Yu H, et al. (2009) Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure. Int J Cardiol 134: 82-90.
48. Arola OJ, Saraste A, Pulkki K, Kallajoki M, Parvinen M, et al. (2000) Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res 60: 1789-1792.
49. Mitchell JB, Anver MR, Sowers AL, Rosenberg PS, Figueroa M, et al. (2012) The antioxidant tempol reduces carcinogenesis and enhances survival in mice when administered after nonlethal total body radiation. Cancer Res 72: 4846-4855.
50. Gurusamy N, Das DK, (2009) Autophagy, redox signaling, and ventricular remodeling. Antioxid Redox Signal 11: 1975-1988.
51. Sishi BJ, Loos B, van Rooyen J, Engelbrecht AM, (2013) Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochem Pharmacol 85: 124-134.
52. Mitchell JB, DeGraff W, Kaufman D, Krishna MC, Samuni A, et al. (1991) Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch Biochem Biophys 289: 62-70.
53. Hahn SM, Tochner Z, Krishna CM, Glass J, Wilson L, et al. (1992) Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res 52: 1750-1753.
54. Cunniff B, Benson K, Stumpff J, Newick K, Held P, et al. (2013) Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells. J Cell Physiol 228: 835-45.
55. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E, (2008) The antioxidant properties of serum albumin. FEBS Lett 582: 1783-1787.
56. Kuller LH, Eichner JE, Orchard TJ, Grandits GA, McCallum L, et al. (1991) The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. Am J Epidemiol 134: 1266-1277.
57. Stevenson FT, Greene S, Kaysen GA, (1998) Serum alpha 2-macroglobulin and alpha 1-inhibitor 3 concentrations are increased in hypoalbuminemia by post-transcriptional mechanisms. Kidney Int 53: 67-75.